Curium US LLC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

2 in Phase 3

Quick facts

Phase 3 pipeline

Abiraterone with Prednisone or Enzalutamide · Oncology
Abiraterone inhibits CYP17A1 to block androgen synthesis, while enzalutamide antagonizes the androgen receptor, together suppressing testosterone-driven prostate cancer growth; prednisone provides glucocorticoid support to mitigate mineralocorticoid excess from abiraterone.
Copper Cu 64 PSMA I&T · Oncology
Copper Cu 64 PSMA I&T is a radioactive diagnostic and therapeutic agent that binds to prostate-specific membrane antigen (PSMA) on cancer cells for imaging and treatment.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

Frequently asked questions about Curium US LLC

What is Curium US LLC's pipeline?

Curium US LLC has 2 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include Abiraterone with Prednisone or Enzalutamide, Copper Cu 64 PSMA I&T.

Sector hub: All tracked pharma companies